SEARCH THE OnBioVC DATABASE:
OnBioVC NEWS:

- OnBioVC 4Q11 Trend Analysis, now available
- OnBioVC 1Q12 White Paper, now available
- OnBioVC 1Q12 Trend Analysis, coming soon

22

Jul

2009

Allostera Pharma, Inc.: Series C $15.4M

Posted in I - Series C, Q - 3Q09, R - INTERNATIONAL, X - Autoimmune, X - Diabetes, X - Gout, X - Psoriatic Arthritis

Allostera Pharma (Canada) a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes, closed a $15.4M Series C financing. Participants include iNovia Capital, Genesys Capital, BDC Venture Capital and GO Capital.

Venture Capital Investors

5AM Ventures Aberdare Ventures Advanced Technology Ventures Alta Partners Amgen Ventures ARCH Venture Partners Bay City Capital Bessemer Venture Partners Canaan Partners Clarus Ventures Delphi Ventures Domain Associates Edmond de Rothschild Investment Partners Flagship Ventures Forbion Capital Partners Forward Ventures HBM Bioventures Healthcare Ventures HLM Venture Partners Interwest Partners Kleiner Perkins Latterell Venture Partners Lilly Ventures Mohr Davidow Ventures MPM Capital New Enterprise Associates New Leaf Venture Partners Novartis Venture Fund Novo Ventures OrbiMed Pappas Ventures Polaris Venture Partners Prospect Venture Partners Quaker BioVentures Sanderling Ventures Sofinnova Partners Sofinnova Ventures SR One SV Life Sciences Third Rock Ventures TPG Biotech TVM Capital U.S. Venture Partners Venrock Versant Ventures

OnBioVC Friends

FluidicMEMES
IguanaBio
EyeOnFDA
Patent Baristas
Pharma's Cutting Edge
MedTechIQ
The Antibody Blog
BioJobBlog

OnBioVC Partners